ALCHEMIA REPORTS NET LOSS OF $15.8M

ALCHEMIA REPORTS NET LOSS OF $15.8M

BRISBANE biotech company Alchemia (ASX:ACL) has reported a net loss of $15.8 million for the first half of the 2015 financial year, compared to $5.5 million for the six months ending 31 December 2013.

A contributing factor of this result was the failure of its recent cancer drug trial.

The pivotal phase three clinical trial of HA-Irinotecan in metastatic colorectal cancer failed to reach its primary endpoint in significant improvement in progression free survival and did not meet its secondary endpoint of an improvement in overall-survival.

This led to shares dropping by 83 per cent from 51.5 cents to 10.5 cents, in November 2014. 

Since the announcement of the above results, ACL has undergone a strategic review of all its assets and operations.

In addition, ACL has recorded profit share income arising from sales of fondaparinux - a collaboration agreement with Dr Reddy's Laboratories - of $2.8 million for the period and had net assets of $11.6 million.

In addition, operating expenditure of $24.9 million increased by $14.2 million over the corresponding period.

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

AI-driven Evitat platform creates pathway to a more sustainable building and renovation industry
Partner Content
Evitat, an AI-driven data platform, is empowering design and build professionals in the...
Evitat
Advertisement

Related Stories

SEEK hit by $141m impairment for Chinese jobs site Zhaopin

SEEK hit by $141m impairment for Chinese jobs site Zhaopin

Online employment marketplace SEEK (ASX: SEK) has taken a hit from ...

"End of an era": me&u founder Stevan Premutico steps down from board

"End of an era": me&u founder Stevan Premutico steps down from board

Stevan Premutico, a pioneer in QR code restaurant ordering and digi...

ANZ is embroiled in allegations it manipulated government bond sales – what exactly does that mean?

ANZ is embroiled in allegations it manipulated government bond sales – what exactly does that mean?

ANZ is being investigated by the Australian Securities and Investme...

ASX biotech minnow Hexima raising $4m to buy and become autonomous intelligence company RealThing

ASX biotech minnow Hexima raising $4m to buy and become autonomous intelligence company RealThing

More than two years after losing 87 per cent of its value in a sing...